To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients.
Patients will be randomized to 1 of 3 doses of oral LXR015-1 for 28 days and patients will be monitored for adverse events for the duration of the study. Patients will continue to be monitored for least 4 weeks after completion of the dosing.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Enrollment
30
East Bay AIDS Ctr
Berkeley, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.